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Introduction {#sec1}
============

Mutations in leucine-rich repeat kinase 2 (*LRRK2*) are associated with both familial and sporadic Parkinson\'s disease (PD), and exhibit clinical symptoms and pathology typical of sporadic PD ([@bib19]). The G2019S mutation is the most common and confers hyper-kinase activity, but it is unclear how the gain of function in kinase activity results in PD pathogenesis. The precise biological function of LRRK2 remains largely unknown, but increasing evidence suggests that mutations in *LRRK2* contribute to mitochondrial dysfunction and oxidative stress ([@bib66], [@bib39], [@bib55], [@bib38]).

*In vivo* and *in vitro* studies examining the consequence of *LRRK2* G2019S on mitochondrial health show altered mitochondrial morphology, increased fragmentation, elevated reactive oxygen species (ROS) production, and decreased respiration ([@bib54], [@bib71]). Induced pluripotent stem cell (iPSC) derived neurons generated from homozygous and heterozygous *LRRK2* G2019S patients showed mitochondrial damage ([@bib57]), deficits in basal and maximal respiration, an increase in mitochondrial trafficking ([@bib11]), and increased susceptibility to H~2~O~2~, 6-OHDA, and rotenone ([@bib40], [@bib50]). Factors implicated in dopaminergic vulnerability include higher metabolic activity, increased oxidative stress due to dopamine oxidation, and calcium buffering defects, all of which may converge on mitochondrial malfunction.

We used *LRRK2* G2019S iPSC-derived dopaminergic, glutamatergic, and sensory neurons to explore functionally relevant mitochondrial parameters by which neurons may be susceptible to disease. We focused on addressing two key questions. First, we asked if the *LRRK2* G2019S mutation causes consistent mitochondrial changes across multiple neuronal subtypes. We found that mitochondrial respiration deficits were observed in *LRRK2* G2019S iPSC-derived dopaminergic and glutamatergic neuron cultures, whereas no mitochondrial defects were observed in *LRRK2* G2019S iPSC-derived peripheral sensory neuron cultures, suggesting a shared CNS weakness. However, *LRRK2* G2019S iPSC-derived dopaminergic neurons displayed additional mitochondrial distribution and trafficking abnormalities, indicating a unique midbrain dopaminergic phenotype. Second, we asked what cellular mechanisms may contribute to the unique mitochondrial phenotypes observed in dopaminergic neuron cultures. Accumulating evidence suggests that protein acetylation is a key regulatory mechanism in mitochondrial function. Sirtuins are protein lysine deacetylases that are localized to the nucleus, cytosol, and mitochondria, where they serve a variety of anti-aging and metabolic roles ([@bib4], [@bib22], [@bib25], [@bib2]). Humans encode seven distinct sirtuins that harbor various roles in mitochondrial biogenesis, movement, and energetics, and collectively may play a role in the defects observed in PD dopaminergic neurons. Surprisingly, we found that *LRRK2* G2019S iPSC-derived dopaminergic neurons exhibit increased sirtuin levels, but decreased deacetylase activity compared with control cells. Because sirtuins require nicotinamide adenine dinucleotide (NAD^+^) as a co-substrate to catalyze deacetylation, we assessed NAD^+^ levels and observed a decreased NAD^+^ pool in *LRRK2* G2019S dopaminergic neurons compared with healthy dopaminergic neurons. The decrease in NAD^+^ correlated with elevated acetylation of sirtuin substrates p53, α-tubulin, and SOD2. Together, these data suggest that *LRRK2* G2019S confers cell-type specific bioenergetic defects, and that dopaminergic neurons may be more significantly impacted in PD due to low endogenous NAD^+^ levels and reduced sirtuin deacetylase activity.

Results {#sec2}
=======

*LRRK2* G2019S iPSC-Derived Dopaminergic Neurons Display Altered Mitochondrial Content and Distribution {#sec2.1}
-------------------------------------------------------------------------------------------------------

To examine mitochondrial health across neuronal subtypes expressing the *LRRK2* G2019S mutation, we utilized human iPSCs derived from three independent *LRRK2* G2019S patients and three unaffected control individuals ([@bib58]) and differentiated the cells toward midbrain dopaminergic neurons, forebrain glutamatergic neurons, and peripheral sensory neurons. Importantly, we have previously shown that neurons from these *LRRK2* G2019S iPSC lines have consistently elevated expression of phosphorylated LRRK2 at serine 935, but similar levels of total LRRK2 protein compared with the control iPSC neurons ([@bib58]).

We first examined overall mitochondrial content and distribution across the three neuronal subtypes. Cells were immunostained for the mitochondrial membrane protein TOM20 and co-labeled with tyrosine hydroxylase (TH), βIII-tubulin (TUJ1), or peripherin to mark dopaminergic, glutamatergic, and sensory neurons, respectively ([Figures 1](#fig1){ref-type="fig"}A, 1D, 1G, and [S1](#mmc1){ref-type="supplementary-material"}A). Immunofluorescence ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and western blot analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}C) for the NMDA receptor 2B subunit (NR2B) were used to further confirm glutamatergic neuron identity. Consistent with our previous report ([@bib58]), there was no difference in differentiation efficiency across the individual cell lines ([Figures 1](#fig1){ref-type="fig"}B, 1E, and 1H), and differentiation efficiencies were consistent with other reports in the literature ([@bib5], [@bib6], [@bib29]). Using immunofluorescence intensity ([Figures 1](#fig1){ref-type="fig"}C, 1F, and 1I) and western blot analysis ([Figure 1](#fig1){ref-type="fig"}J), mitochondrial content was reduced in *LRRK2* G2019S iPSC-derived dopaminergic neurons compared with controls, but not in the other neuronal subtypes. We next measured mitochondrial distribution along the neurite and divided the data points into four equal quartiles to assess differences in proximal versus distal distribution. Because we and others have shown that *LRRK2* G2019S iPSC-derived dopaminergic neurons exhibit shortened neurites ([@bib11], [@bib56], [@bib50], [@bib58]), quartiles were determined relative to each neuronal subtype and not compared across neuron types. *LRRK2* G2019S iPSC-derived dopaminergic neurons displayed significantly reduced mitochondrial distribution along the distal neurite length ([Figure 1](#fig1){ref-type="fig"}K). In contrast to previous reports using mouse cortical neurons expressing *LRRK2* G2019S ([@bib10]), neither mitochondrial content nor distribution was diminished in *LRRK2* G2019S glutamatergic and sensory neurons compared with control neurons ([Figures 1](#fig1){ref-type="fig"}F, 1I, 1L, and 1M), suggesting neuron specific mitochondrial properties in human *LRRK2* G2019S conditions.Figure 1*LRRK2* G2019S iPSC-Derived Dopaminergic Neurons Display Altered Mitochondrial Content and DistributionRepresentative images of each individual control line (1, 2, and 3) and each individual *LRRK2* G2019S iPSC line (het, 1, and 2) immunostained for (A) tyrosine hydroxylase (TH, red), (D) βIII-tubulin (TUJ1, green), and (G) peripherin (red) to mark dopaminergic, glutamatergic, and sensory neurons, respectively. Nuclei labeled with Hoechst (blue). Scale bars, 50 μm. Quantification of differentiation efficiency (B, E, and H), mitochondrial content (C, F, and I), TOM20 protein (J), and mitochondrial distribution (K, L, and M) compared by one-way repeated measures ANOVA with Tukey\'s *post-hoc* test. n.s., not significant. ^∗∗^p \< 0.01 in (C) indicates that all three *LRRK2* samples are significantly reduced compared with all three control samples. ^∗^p \< 0.05 in (I) indicates that control 1 is significantly reduced compared with *LRRK2* 1 and 2. ^∗^p \< 0.05 in (J) indicates that all three *LRRK2* samples are significantly reduced compared with all three control samples. ^∗^p \< 0.05 in (K) indicates that *LRRK2* het is different from all three controls (0%--25%) and all three *LRRK2* lines are different from all three control lines for 25%--50%, 50%--75%, and 75%--100%. ^∗^p \< 0.05 in (L) indicates that *LRRK2* 1 is significantly different from all samples at 0%--25%. ^∗^p \< 0.05 in (M) indicates that control 2 and 3 are different from *LRRK2* het and *LRRK2* 1 at 0%--25% and 25%--50%, and that *LRRK2* 1 is different from all three controls at 50%--75% and 75%--100%. n = 4 independent experiments. All error bars are SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

*LRRK2* G2019S iPSC-Derived Dopaminergic Neurons Display Increased Mitochondrial Velocity and Motility {#sec2.2}
------------------------------------------------------------------------------------------------------

Neurons depend on regulated mitochondrial trafficking to match energy demand and to control the clearance of damaged mitochondria ([@bib1]). We utilized live-cell imaging to investigate if *LRRK2* G2019S induced changes in mitochondrial trafficking and mobility within iPSC-derived dopaminergic, glutamatergic, and sensory neurons. We observed an increase in mitochondrial velocity in *LRRK2* G2019S iPSC-derived dopaminergic neurons compared with control dopaminergic neurons ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, neither *LRRK2* G2019S glutamatergic nor sensory neurons were altered compared with their respective control neurons ([Figure 2](#fig2){ref-type="fig"}A). Similar to a previous study ([@bib11]), we also saw an increase in the percentage of mobile mitochondria in dopaminergic neurons, but this effect was not observed in *LRRK2* G2019S glutamatergic or sensory neurons ([Figure 2](#fig2){ref-type="fig"}B). Finally, we found that *LRRK2* G2019S iPSC-derived dopaminergic neurons display increased retrograde mitochondrial velocity ([Figure 2](#fig2){ref-type="fig"}C), which correlates with diminished mitochondrial content in the distal neurite ([Figure 1](#fig1){ref-type="fig"}K). Together, these data highlight intrinsic dopaminergic neuron mitochondrial trafficking deficits.Figure 2*LRRK2* G2019S iPSC-Derived Dopaminergic Neurons Display Increased Mitochondrial Velocity and MotilityMeasurements of (A) mitochondrial velocity (μm/s), (B) percent mobile mitochondria, and (C) direction of mitochondrial movement are shown for each individual iPSC line. There was a significant difference for each of the three *LRRK2* lines compared with each of the control lines in the dopaminergic neuron cultures, but not in either the glutamatergic or sensory neuron cultures. n.s., not significant. ^∗^p \< 0.05 and ^∗∗^p \< 0.01 by one-way repeated measures ANOVA with Tukey\'s *post-hoc* test. n = 4 independent experiments. All error bars are SEM. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Mitochondrial Respiration Is Decreased in *LRRK2* G2019S iPSC-Derived Dopaminergic and Glutamatergic Neurons {#sec2.3}
------------------------------------------------------------------------------------------------------------

We next asked if mitochondrial bioenergetics was affected in *LRRK2* G2019S iPSC-derived neurons. Control and *LRRK2* G2019S iPSCs were differentiated into dopaminergic, glutamatergic, and sensory neurons to measure oxygen consumption rate (OCR) ([@bib14], [@bib72], [@bib45]). Basal glycolytic rates were not changed in any of the *LRRK2* G2019S neurons compared with controls (data not shown). However, consistent with previous studies ([@bib38], [@bib37], [@bib11], [@bib43]), we observed a marked decrease in OCR for ATP-linked ([Figure 3](#fig3){ref-type="fig"}A), maximal ([Figure 3](#fig3){ref-type="fig"}B), and spare respiration ([Figure 3](#fig3){ref-type="fig"}C) in *LRRK2* G2019S dopaminergic neuron cultures compared with control dopaminergic neuron cultures. Interestingly, we also observed a decrease in these same parameters for *LRRK2* G2019S forebrain glutamatergic neuron cultures compared with control, but not in *LRRK2* G2019S sensory neuron cultures ([Figures 3](#fig3){ref-type="fig"}A--3C). Together, these data suggest that *LRRK2* G2019S may preferentially alter mitochondrial respiration rates of central neurons and spare peripheral neurons.Figure 3Mitochondrial Respiration Is Decreased in *LRRK2* G2019S iPSC-Derived Dopaminergic and Glutamatergic CulturesAll three *LRRK2* G2019S iPSC-derived dopaminergic and glutamatergic cultures display diminished (A) ATP-linked, (B) maximal, and (C) spare respiration compared with all three of the respective control cultures. *LRRK2* G2019S iPSC-derived sensory neurons are unchanged compared with controls. ^∗^p \< 0.05 by one-way repeated measures ANOVA with Tukey\'s *post-hoc* test. n = 4 independent experiments. All error bars are SEM. See also [Figures S2, S3](#mmc1){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}.

Consistent with the observed decrease in bioenergetics, *LRRK2* G2019S dopaminergic cultures displayed diminished ATP and ADP levels compared with control neurons, whereas *LRRK2* G2019S glutamatergic cultures displayed changes only in ATP levels ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). No change was observed in sensory neuron cultures ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). To further assess the reduction in ATP levels, we examined components of the electron transport chain by western blot using the OXPHOS antibody cocktail. Complex I (NDUFB8) and IV (COX II) were undetectable in all neuron cultures, and complex V (ATP5A) and II (SDHB) levels were unchanged ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). However, the levels of complex III (UQCRC2) were significantly decreased in both dopaminergic and glutamatergic neuron cultures from *LRRK2* G2019S iPSCs compared with control ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Therefore, it is possible that decreased expression or increased degradation of complex III in *LRRK2* G2019S iPSC-derived dopaminergic and glutamatergic neuron cultures alters proton transport, thereby diminishing the proton gradient necessary for ATP production.

LRRK2 Kinase Inhibition Using GSK2578215A Does Not Restore Mitochondrial Dysfunction {#sec2.4}
------------------------------------------------------------------------------------

Since the G2019S mutation confers hyper-kinase activity ([@bib68], [@bib21], [@bib26], [@bib33]), we tested whether LRRK2 kinase inhibition using GSK2578215A ([@bib51]) could rescue the observed mitochondrial defects in *LRRK2* G2019S iPSC-derived neurons. We have previously shown that treatment with 1 μM GSK2578215A reduced expression of phosphorylated LRRK2 in *LRRK2* G2019S iPSC-derived neurons ([@bib58]). Therefore, we treated dopaminergic, glutamatergic, and sensory neuron cultures with GSK2578215A (1 μM) for 1 week prior to endpoint analysis. However, LRRK2 kinase inhibition only showed an effect in the *LRRK2* G2019S Het line for mitochondrial velocity, but there was no effect in any *LRRK2* G2019S line for ATP-linked, maximal, and spare respiration in dopaminergic neurons. GSK2578215A did not have a positive or negative effect on glutamatergic and sensory neurons ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). These results suggest that increased kinase activity is not directly contributing to mitochondrial malfunction in this model system.

*LRRK2* G2019S Dopaminergic Neuron Cultures Show Increased Sirtuin Expression but Decreased Deacetylase Activity {#sec2.5}
----------------------------------------------------------------------------------------------------------------

Sirtuins are a family of NAD^+^-dependent protein deacetylases that regulate many cellular processes, and changes in sirtuin expression levels may contribute to altered mitochondrial production, metabolism, and movement ([@bib4], [@bib22], [@bib25]). Sirtuin-1 (SIRT1) has been shown to localize to the cytoplasm and nucleus where it plays a role in mitochondrial biogenesis ([@bib64]). Western blot analysis of SIRT1 revealed a significant increase in *LRRK2* G2019S iPSC-derived dopaminergic neurons compared with control cells in which SIRT1 levels were below the detection limit ([Figures 4](#fig4){ref-type="fig"}A and 4B). SIRT1 deacetylates and activates PGC1α ([@bib53], [@bib31], [@bib3], [@bib69]), which is an essential metabolic regulatory transcription factor. As expected based on the decreases in mitochondrial respiration and ATP pool, the levels of PGC1α were markedly decreased in iPSC-derived *LRRK2* G2019S dopaminergic cultures ([Figures 4](#fig4){ref-type="fig"}C and 4D). In contrast, there was no difference in SIRT1 or PGC1α expression in *LRRK2* G2019S glutamatergic cultures compared with control cultures ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). Acetylated p53 is a known direct target of SIRT1 and showed a trend toward increased expression in *LRRK2* G2019S iPSC-derived dopaminergic neurons compared with controls ([Figures 4](#fig4){ref-type="fig"}E and 4F), indicating reduced SIRT1 activity.Figure 4*LRRK2* G2019S Dopaminergic Neuron Cultures Show Altered Levels of Sirtuin-1, PGC1α, and Acetylated p53(A and B) Western blot analysis revealed a significant increase in (A and B) SIRT1 in all three *LRRK2* G2019S iPSC-derived dopaminergic cultures compared with the three controls. REVERT was used as a loading control.(C and D) In contrast, PGC1α expression levels were significantly reduced in all three *LRRK2* G2019S iPSC-derived dopaminergic cultures compared with controls. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control.(E and F) Levels of acetylated-p53 were increased in *LRRK2* G2019S iPSC-derived dopaminergic cultures, although this did not reach significance. REVERT was used as a loading control.n.s., not significant. ^∗^p \< 0.05 by one-way ANOVA with Tukey\'s *post-hoc* test. n = 3 independent experiments. All error bars are SEM. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Sirtuin-2 (SIRT2) is known to mediate microtubule-based cellular trafficking through its effect on tubulin acetylation ([@bib41]). Considering the significant alterations in mitochondrial movement in *LRRK2* G2019S iPSC-derived dopaminergic neurons ([Figure 2](#fig2){ref-type="fig"}), we tested whether SIRT2 expression and/or activity were likewise disrupted. Similar to SIRT1, SIRT2 protein levels were significantly increased in *LRRK2* G2019S iPSC-derived dopaminergic neurons compared with control ([Figures 5](#fig5){ref-type="fig"}A and 5B), but deacetylase activity was impaired as noted by the significant increase in the levels of acetylated α-tubulin ([Figures 5](#fig5){ref-type="fig"}A and 5C).Figure 5*LRRK2* G2019S Dopaminergic Neuron Cultures Show Increased Sirtuin-2 and Acetylated TubulinWestern blot analysis revealed a significant increase in (A and B) SIRT2 and (A and C) acetylated tubulin expression in all three *LRRK2* G2019S iPSC-derived dopaminergic cultures compared with controls. REVERT was used as a loading control for both targets. ^∗^p \< 0.05 by one-way ANOVA with Tukey\'s *post-hoc* test. n = 3 independent experiments. All error bars are SEM.

Next, we tested sirtuin-3 (SIRT3) levels and activity as SIRT3 is the primary mitochondrial deacetylase shown to regulate mitochondrial bioenergetics and ATP generation ([@bib67]). Immunoblot analysis of SIRT3 expression levels revealed significantly increased expression in *LRRK2* G2019S dopaminergic cultures compared with control ([Figures 6](#fig6){ref-type="fig"}A and 6B). There was a trend toward a decrease in SIRT3 activity based on higher levels of acetylated SOD2 ([Figures 6](#fig6){ref-type="fig"}C and 6D). Although the changes associated with SOD2 did not reach significance, the trend is consistent with an overall diminished deacetylase activity in PD dopaminergic neurons. There was no difference in SIRT3 levels between control and *LRRK2* G2019S glutamatergic neurons ([Figure S6](#mmc1){ref-type="supplementary-material"}). To determine whether increased SIRT levels were associated with excessive kinase activity, we tested whether GSK2578215A was sufficient to lower SIRT levels. However, similar to a lack of effect on mitochondrial dysfunction, we did not observe changes in SIRT1, SIRT2, or SIRT3 expression levels (data not shown).Figure 6*LRRK2* G2019S Dopaminergic Neuron Cultures Show Increased Sirtuin-3 and Acetylated SOD2Western blot analysis revealed a significant increase in (A and B) SIRT3 expression and (C and D) a trend toward increased acetylated SOD2 expression in *LRRK2* G2019S iPSC-derived dopaminergic cultures compared with control. SIRT3 was normalized to GAPDH, and SOD2 was normalized to REVERT. n.s., not significant. ^∗^p \< 0.05 by one-way ANOVA with Tukey\'s *post-hoc* test. n = 3 independent experiments. All error bars are SEM. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Since sirtuins require NAD^+^ as a co-substrate to catalyze deacetylation, we hypothesized that low sirtuin activity in *LRRK2* G2019S iPSC-derived dopaminergic neurons was due to low NAD^+^ levels. Indeed, NAD^+^ levels were significantly decreased in *LRRK2* G2019S dopaminergic neurons compared with controls, a deficiency that was not observed in the other neuronal subtypes ([Figure 7](#fig7){ref-type="fig"}). Taken together, these data suggest that diminished NAD^+^ levels limit sirtuin deacetylase activity in *LRRK2* G2019S iPSC-derived dopaminergic neurons, and may underlie the mitochondrial malfunction observed in this system and contribute to selective dopaminergic neuron loss in PD.Figure 7*LRRK2* G2019S Dopaminergic Neurons Exhibit Significantly Reduced NAD^+^ LevelsHPLC analysis revealed that all three *LRRK2* G2019S expressing dopaminergic neurons have significantly reduced NAD^+^ levels compared with controls. There was no difference between control and *LRRK2* G2019S-expressing neurons for either glutamatergic or sensory neuron cultures. n.s., not significant. ^∗^p \< 0.05 compared with control dopaminergic neurons by one-way repeated measures ANOVA with Tukey\'s *post-hoc* test. n = 3 independent experiments. All error bars are SEM.

Discussion {#sec3}
==========

Evidence from *in vitro* and *in vivo* studies suggest that mitochondrial malfunction is a common characteristic in PD. Consistent with these reports, we show that *LRRK2* G2019S iPSC-derived neurons display mitochondrial abnormalities, including altered content, distribution, trafficking, and respiration, which appear to be independent of increased kinase activity; interestingly, these mitochondrial defects manifest differently depending upon neuron subtype, with dopaminergic neuron cultures exhibiting the most profound changes compared with glutamatergic or sensory neuron cultures.

Regulation of mitochondrial distribution is essential to meet metabolic requirements and to remove aged and damaged mitochondria. The decreased content and reduced distal distribution of mitochondria within dopaminergic neurons may be due to damaged mitochondria being removed by autophagy or an inability to sufficiently replenish the neurites with healthy mitochondria, which has been reported for *LRRK2* G2019S expressing mouse cortical neurons and SH-SY5Y cells ([@bib10]). This result is in contrast to our data for *LRRK2* G2019S iPSC-derived glutamatergic neuron cultures. The discrepancy may be due to inherent differences between the model systems. In addition, the default forebrain telencephalic neuron patterning utilized here ([@bib16], [@bib28]) may not fully recapitulate the maturity and cell-type specificity found within the mouse cortex. Additional studies using specific iPSC cortical patterning techniques may be necessary to address the discrepancy ([@bib36], [@bib61]).

The distribution of mitochondria within neurons is dependent on efficient and regulated mitochondrial trafficking. The transport and function of mitochondria are linked as mitochondria supply ATP energy to motor proteins to transport them along the cytoskeleton to areas of high energy demand ([@bib59]). Thus, abnormalities in mitochondrial trafficking may lead to abnormal mitochondrial distribution and protein transport and ultimately result in cellular dysfunction. We show that *LRRK2* G2019S can affect mitochondrial trafficking based on increased retrograde mitochondrial velocity and mobile mitochondria in *LRRK2* G2019S iPSC-derived dopaminergic neurons. These data correlate well with diminished mitochondrial content in the distal neurite. The trafficking results presented here are in contrast to a study using PD sporadic mitochondrial NT2 cybrids that showed a decline in overall mitochondrial velocity and a decrease in the percent mobile mitochondria ([@bib17]), but do support the findings in SH-SY5Y cultures ([@bib12]), and in *LRRK2* G2019S and PINK1 Q456X expressing neurons ([@bib11]). The increase in percent mobile mitochondria within *LRRK2* G2019S dopaminergic neurons suggests that the balance between motile and stationary mitochondria is perturbed. Anchored mitochondria provide local energy sources within neurons and are crucial to ensure that metabolically active areas are supplied with ATP, especially at presynaptic terminals. Moreover, stationary mitochondria are also required for axonal branching and maintenance ([@bib27]). Therefore, disruption in stationary mitochondria may explain the deficient neurite elongation and branching that we and others have observed in *LRRK2* G2019S-expressing neurons ([@bib34], [@bib47], [@bib9], [@bib49], [@bib11], [@bib56], [@bib50], [@bib58]). However, additional studies are needed to establish a specific link between *LRRK2* G2019S and mitochondrial motility.

The LRRK2 kinase inhibition results suggest that increased kinase activity due to the G2019S *LRRK2* mutation is not directly contributing to the mitochondrial and SIRT abnormalities in this iPSC-based system. Although GSK2578245A has been shown to be selective for LRRK2 kinase inhibition ([@bib51]), and we previously observed beneficial effects on morphology and calcium response in *LRRK2* G2019S iPSC-derived sensory neurons ([@bib58]), it is possible that a different kinase inhibitor or treatment paradigm would be more effective.

A number of studies have tested the effect of modifying SIRT1, SIRT2, or SIRT3 in PD models, but the results have been mixed. For example, increasing levels of SIRT1 or SIRT3 protect dopaminergic neurons from toxin-induced cell death ([@bib64]). In contrast, most data indicate that inhibiting SIRT2 expression is neuroprotective in PD models ([@bib42], [@bib20], [@bib30], [@bib8], [@bib13]), although another study suggested otherwise ([@bib44]). More research is needed to determine the specific contributions of the various sirtuins to PD, but the divergent effects of sirtuin upregulation and inhibition may be due to the different targets of the individual sirtuins. Importantly, previous studies have not examined the levels of NAD^+^ necessary for sirtuin activity in human dopaminergic neurons.

Recent studies have shown that PGC1α and SIRT1 play key roles in cell metabolism and mitochondrial biogenesis ([@bib53], [@bib52]). PGC1α is active in the deacetylated form, which is achieved by the deacetylase function of SIRT1, and plays a protective role in ROS defense. Here we show lower expression levels of active PGC1α in *LRRK2* G2019S iPSC-derived dopaminergic neuron cultures compared with glutamatergic neuron cultures. We also found a strong trend toward increased acetylated p53 (∼2- to 3-fold) in *LRRK2* G0291S iPSC-derived dopaminergic neurons compared with controls, a direct target of SIRT1, which may contribute to the vulnerability of dopaminergic neurons to oxidative stress in PD. To support this idea, acetylation of p53 at Lys382, the residue recognized by the antibody used here, is directly associated with activation of apoptosis and ROS production ([@bib70]). Similarly, a small-molecule activator of PGC1α resulted in enhanced resistance against oxidative stress in human dopaminergic neurons ([@bib35]).

SIRT2 is localized to the cytoplasm and, together with HDAC6, is largely responsible for deacetylation of α-tubulin ([@bib41]). Studies have shown that increasing acetylated α-tubulin, through inhibition of HDAC6, increases mitochondrial movement in hippocampal neurons ([@bib7]). Our studies are consistent with this notion as we find significantly increased mitochondrial velocity and retrograde trafficking in the *LRRK2* G2019S iPSC-derived dopaminergic neurons. Mutant *LRRK2* has been shown to associate with deacetylated tubulin and disrupt vesicle trafficking ([@bib20]). However, our data suggest that the altered mitochondrial trafficking may be independent of mutant *LRRK2* as neither *LRRK2* G2019S-expressing glutamatergic neurons nor sensory neurons exhibit altered mitochondrial trafficking, and the *LRRK2* kinase inhibitor GSK2578215A did not improve trafficking defects in dopaminergic neurons. It is important to note that our data are in contrast to a recent report showing that NAD^+^ levels and SIRT2 deacetylase activity were increased in PD patient-derived cybrid cell lines ([@bib18]). This discrepancy could be due to differences between the cybrid and iPSC model systems, but another plausible explanation could be due to variations in NAD^+^ levels among different cell types, as demonstrated by the variable levels in dopaminergic, glutamatergic, and sensory neurons.

As the main mitochondrial deacetylase, SIRT3 has also been shown to regulate many aspects of mitochondrial function, including metabolism, ATP generation, and limiting oxidative stress ([@bib60], [@bib23], [@bib32]). Mechanistically, SIRT3 has been directly linked to reducing ROS production through activation of SOD2 ([@bib48], [@bib63], [@bib65]). In PD, SIRT3 has been implicated as a causative factor in dopaminergic neuron loss in MPTP- and rotenone-treated neurons ([@bib73], [@bib74]). Although we observe increased SIRT3 protein levels in *LRRK2* G2019S iPSC-derived dopaminergic neurons, as was the case for SIRT1 and SIRT2, increased expression did not correlate with increased activity, which is likely due to lower NAD^+^ levels in *LRRK2* G2019S iPSC-derived dopaminergic cultures.

Our data demonstrate unique, and potentially LRRK2 kinase-independent, changes in sirtuin activity and NAD^+^ levels in human dopaminergic neurons expressing the *LRRK2* G2019S PD-associated mutation and may underlie pathological mechanisms of dopaminergic neuron loss in PD. The results of these studies also provide further insight into the role of sirtuins in dopaminergic neurons and stress the importance of considering NAD^+^ levels in conjunction with sirtuin activity when designing therapeutic intervention for the treatment of PD.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Human iPSCs were obtained from publically available samples derived from two homozygous *LRRK2* G2019S patients (ND35367^∗^C, ND40018^∗^C Coriell Institute) and one heterozygous *LRRK2* G2019S patient (ND40019^∗^C Coriell Institute). Three previously characterized unaffected control lines were used (GM003814 Coriell Institute, GM02183 Coriell Institute, iPSK3; [@bib15], [@bib62], [@bib24]). A table describing the demographic, reprogramming, and source information for the control and PD iPSC lines is provided in our previously published work ([@bib58]). Karyotypically normal iPSCs, used between passages 5 and 10, were grown in feeder-free conditions on Matrigel substrate in StemMACS iPS-Brew (Miltenyi). Karyotype G-banding was performed by Cell Line Genetics (Madison, WI). Neural progenitor cells (EZ spheres) were generated and maintained as described previously ([@bib16]). The use of iPSCs was approved by the Medical College of Wisconsin\'s Institutional Review Board (PRO25822) and the Human Stem Cell Research Oversight Committee.

Neural Differentiation {#sec4.2}
----------------------

EZ spheres were differentiated into dopaminergic neurons using fibroblast growth factor-8, purmorphamine, and growth factors as described previously ([@bib16]). Telencephalic excitatory projection neurons were derived from EZ spheres as described previously ([@bib16]). Sensory neurons were derived from monolayer iPSCs as described previously ([@bib6]). For LRRK2 kinase inhibition experiments, 1 μM GSK2578215A (Tocris) was added at every feeding starting at 1 week prior to endpoint analysis. DMSO (1 μM) was used as the vehicle control. All analyses were performed at 5 weeks of total differentiation for dopaminergic neurons and 4 weeks of total differentiation for glutamatergic and sensory neurons.

Immunocytochemistry {#sec4.3}
-------------------

Plated cells were fixed in 4% paraformaldehyde in PBS (pH 7.4) for 20 min at room temperature. Nonspecific labeling was blocked and the cells permeabilized prior to primary antibody incubation. Cells were subsequently labeled with the appropriate fluorescently tagged secondary antibodies. Hoechst nuclear dye was used to label nuclei. Antibodies are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

Western Blot {#sec4.4}
------------

Whole-cell lysates were isolated from dopaminergic and glutamatergic neuron cultures using 1× 3-\[(3-cholamidopropyl)dimethylammonio\]-1-propanesulfonate (CHAPS) Cell Extract buffer with protease inhibitors (Cell Signaling Technology). Twenty micrograms of protein was run on 10% Tris-HCl polyacrylamide gels (Bio-Rad), transferred to polyvinylidene fluoride membrane (Millipore), and probed following standard chemiluminescent methods. Alternatively, membranes were probed following the LI-COR fluorescent western blot protocol and scanned using the Odyssey Infrared Imaging System. Protein quantifications were normalized using glyceraldehyde-3-phosphate dehydrogenase or REVERT Total Protein Stain. Antibodies are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

Mitochondrial Content and Distribution {#sec4.5}
--------------------------------------

Images were acquired from five random fields per coverslip and then analyzed using region of interest and line scan tools included in NIS Elements software. For region of interest measurements, the entire neuron was automatically traced and then TOM20 intensity was measured over this area. For line scan measurements, neurites projecting from a cell body were randomly selected and then measured for TOM20 intensity along the neurite length. Each neurite measurement was then divided into quartiles with respect to each neurite\'s overall length. A minimum of 250 neurons were analyzed from each line. Only TH+ (dopaminergic), TUJ1+ (glutamatergic), and peripherin+ (sensory neurons) were analyzed.

Mitochondrial Trafficking {#sec4.6}
-------------------------

Plated cells were loaded with 25 nM MitoTracker Green FM (Thermo Scientific; M7514) for 15 min, washed, and imaged on a Nikon fluorescent microscope. Videos were acquired from at least 5 random fields per coverslip, and a minimum of 250 neurons were analyzed and calculated using NIS Element kymograph software. Only the mitochondria found in neurites projecting from clearly identifiable cell bodies were used to determine anterograde and retrograde mitochondrial movement.

Mitochondrial Bioenergetics {#sec4.7}
---------------------------

iPSC lines were seeded onto Seahorse Bioscience 96-well microplates and patterned toward dopaminergic, glutamatergic, and sensory neurons. The plates were analyzed using a standard method for measuring OCR using the XFe96 Extracellular Flux Analyzer ([@bib14], [@bib45]).

Nucleotide Measurements {#sec4.8}
-----------------------

ATP, ADP, and NAD^+^ were analyzed by high-performance liquid chromatography (HPLC) following perchloric acid precipitation, as described previously ([@bib46]). Solvent A (125 μL; 0.1 M potassium phosphate and 4 mM tetrabutylammonium bisulfate \[pH 6.0\], diluted 64:36 in water \[v/v\]) was added to the supernatants (100 μL). Protein concentrations were determined by Bradford assay using 1× CHAPS buffer with PMSF and 1× DTT (Cell Signaling Technology). HPLC analysis of nucleotides was performed on a Supelco C-18 column using solvent A and solvent B (0.1 M potassium phosphate and 4 mM tetrabutylammonium bisulfate \[pH 6.0\], diluted 64:36 in methanol \]v/v\]) with a flow rate of 1 mL/min. The column was equilibrated with solvent A, and the compounds were eluted during a linear increase in the level of solvent B to 50% between 1.5 and 5.5 min, followed by an increase to 65% over the next 7.5 min. ATP, ADP, and NAD^+^ peaks were measured for each sample, compared with the standards, and expressed in nmol per mg of protein.

Statistical Analysis {#sec4.9}
--------------------

Data are from a minimum of three independent experiments, each with a minimum of three biological replicates. Samples were blinded prior to analysis. With consultation from the Department of Biostatistics at the Medical College of Wisconsin, statistical analysis was performed with GraphPad Prism software using one-way ANOVA, one-way repeated measures ANOVA, or two-way repeated measures ANOVA with Tukey *post-hoc* analysis. Results are presented as mean ± SEM and considered statistically significant at p \< 0.05.
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